



## Clinical trial results:

**A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of a prophylactic SARS-CoV-2 RNA vaccine (BNT162b3) against COVID-19 using different dosing regimens in healthy adults**

### Summary

EudraCT number	2020-003267-26
Trial protocol	DE
Global end of trial date	07 February 2022

### Results information

Result version number	v1 (current)
This version publication date	22 February 2023
First version publication date	22 February 2023

### Trial information

#### Trial identification

Sponsor protocol code	BNT162-04
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04537949
WHO universal trial number (UTN)	U1111-1254-4840

Notes:

### Sponsors

Sponsor organisation name	BioNTech SE
Sponsor organisation address	An der Goldgrube 12, Mainz, Germany, 55131
Public contact	BioNTech clinical trials patient information, BioNTech SE, 0049 6131 90840, patients@biontech.de
Scientific contact	BioNTech clinical trials patient information, BioNTech SE, 0049 6131 90840, patients@biontech.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 July 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 February 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To describe the safety and tolerability profiles of a prophylactic BNT162b3 in healthy adults after prime/boost (P/B) immunization.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 September 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 96
Worldwide total number of subjects	96
EEA total number of subjects	96

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	70
From 65 to 84 years	26
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were selected from the volunteer panel at the clinical CRO, who responded to either generic or study-specific advertisements in social media, or who contacted the clinical CRO via a web-based study participant recruitment portal. Participants were selected from this pool of volunteers according to inclusion and exclusion criteria.

### Pre-assignment

Screening details:

All enrolled participants were allocated to treatment.

### Period 1

Period 1 title	Treatment Phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 3 µg

Arm description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.

<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 10 µg
------------------	---

Arm description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.

<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 20 µg
------------------	---

Arm description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Arm type	Experimental
----------	--------------

Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 30 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 3 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 10 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 20 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental

Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.

<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 30 µg
------------------	---

Arm description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.

<b>Number of subjects in period 1</b>	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg
Started	12	12	12
Completed	11	12	12
Not completed	1	0	0
Personal reasons not related to the IMP	1	-	-

<b>Number of subjects in period 1</b>	Part A Participants Aged 18 to 55 Years - 30 µg	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg
Started	12	12	12
Completed	12	12	12
Not completed	0	0	0
Personal reasons not related to the IMP	-	-	-

<b>Number of subjects in period 1</b>	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Started	12	12
Completed	12	12
Not completed	0	0
Personal reasons not related to the IMP	-	-

<b>Period 2</b>	
Period 2 title	Follow-up Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded
<b>Arms</b>	
Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 3 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 10 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 20 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 18 to 55 Years - 30 µg

Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 3 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 10 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 20 µg
Arm description:	
BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.	
<b>Arm title</b>	Part A Participants Aged 56 to 85 Years - 30 µg

Arm description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Arm type	Experimental
Investigational medicinal product name	BNT162b3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two injections administered intramuscularly (upper arm, musculus deltoideus) approximately 21 days apart. Injection volumes were up to 1.5 mL.

<b>Number of subjects in period 2</b>	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg
Started	11	12	12
Completed	8	8	12
Not completed	3	4	0
Personal reasons	-	-	-
Consent withdrawn by subject	-	-	-
Roll-over into trial BNT162-14	3	1	-
Lost to follow-up	-	3	-

<b>Number of subjects in period 2</b>	Part A Participants Aged 18 to 55 Years - 30 µg	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg
Started	12	12	12
Completed	9	9	11
Not completed	3	3	1
Personal reasons	1	1	-
Consent withdrawn by subject	-	1	-
Roll-over into trial BNT162-14	2	1	1
Lost to follow-up	-	-	-

<b>Number of subjects in period 2</b>	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Started	12	12
Completed	7	6
Not completed	5	6
Personal reasons	-	-
Consent withdrawn by subject	-	-
Roll-over into trial BNT162-14	5	6
Lost to follow-up	-	-





## Baseline characteristics

### Reporting groups

Reporting group title	Part A Participants Aged 18 to 55 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).	
Reporting group title	Part A Participants Aged 56 to 85 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	

Reporting group values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg
Number of subjects	12	12	12
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	39.32	31.20	31.89
standard deviation	± 9.79	± 9.11	± 13.51
Gender categorical Units: Subjects			
Female	3	4	7
Male	9	8	5

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	12	12
Unknown or Not Reported	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	12	12	11
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Weight			
Units: kg			
arithmetic mean	72.74	71.68	71.40
standard deviation	± 11.43	± 11.67	± 14.40
Body mass index			
Units: kg/m <sup>2</sup>			
arithmetic mean	23.89	24.23	23.80
standard deviation	± 2.92	± 3.68	± 2.74

<b>Reporting group values</b>	Part A Participants Aged 18 to 55 Years - 30 µg	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg
Number of subjects	12	12	12
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	37.28	66.08	69.32
standard deviation	± 6.40	± 7.16	± 8.74
Gender categorical			
Units: Subjects			
Female	8	9	8
Male	4	3	4
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	12	12
Unknown or Not Reported	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	12	12	12
More than one race	0	0	0

Unknown or Not Reported	0	0	0
-------------------------	---	---	---

Weight Units: kg arithmetic mean standard deviation	71.20 ± 13.80	76.05 ± 11.88	70.90 ± 10.69
Body mass index Units: kg/m <sup>2</sup> arithmetic mean standard deviation	23.69 ± 2.03	25.92 ± 1.66	24.69 ± 3.09

<b>Reporting group values</b>	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg	Total
Number of subjects	12	12	96
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	64.93 ± 6.63	66.42 ± 6.82	-
Gender categorical Units: Subjects			
Female	9	6	54
Male	3	6	42
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	12	96
Unknown or Not Reported	0	0	0
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	12	12	95
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Weight Units: kg arithmetic mean standard deviation	69.06 ± 14.25	84.43 ± 17.53	-
Body mass index Units: kg/m <sup>2</sup> arithmetic mean standard deviation	24.03 ± 3.17	26.73 ± 2.75	-

## End points

### End points reporting groups

Reporting group title	Part A Participants Aged 18 to 55 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).	
Reporting group title	Part A Participants Aged 56 to 85 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 18 to 55 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).	
Reporting group title	Part A Participants Aged 56 to 85 Years - 3 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	

Reporting group title	Part A Participants Aged 56 to 85 Years - 10 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 20 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	
Reporting group title	Part A Participants Aged 56 to 85 Years - 30 µg
Reporting group description: BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)	

**Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose**

End point title	Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose <sup>[1]</sup>
-----------------	--

End point description:

Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Safety Set - all participants who received at least one dose of the IMP. 9999 indicates data not available as the boost immunization was withheld for 30 µg younger cohort following Safety Review Committee decision.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Day 8 for Prime Immunization and from Day 22 to Day 29 for Boost Immunization

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this primary end point.

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
Prime up to Day 7: any local reaction	9	9	12	12
Prime up to Day 7: any grade ≥3 local reaction	0	0	2	2
Boost up to Day 7: any local reaction	9	9	12	9999
Boost up to Day 7: any grade ≥3 local reaction	0	0	1	9999

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
------------------	---	--	--	--

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
Prime up to Day 7: any local reaction	4	10	10	9
Prime up to Day 7: any grade $\geq 3$ local reaction	0	0	0	0
Boost up to Day 7: any local reaction	2	9	8	11
Boost up to Day 7: any grade $\geq 3$ local reaction	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose

End point title	Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose <sup>[2]</sup>
-----------------	--

End point description:

Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Safety Set - all participants who received at least one dose of the IMP. 9999 indicates data not available as the boost immunization was withheld for 30 µg younger cohort following Safety Review Committee decision.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Day 8 for Prime Immunization and from Day 22 to Day 29 for Boost Immunization

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this primary end point.

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
Prime up to Day 7: any systemic reaction	4	10	12	12
Prime up to Day 7: any grade $\geq 3$ systemic reaction	0	0	1	3
Boost up to Day 7: any systemic reaction	10	9	12	9999
Boost up to Day 7: any grade $\geq 3$ systemic reaction	0	2	4	9999

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
Prime up to Day 7: any systemic reaction	3	9	9	10
Prime up to Day 7: any grade ≥3 systemic reaction	0	3	0	2
Boost up to Day 7: any systemic reaction	2	10	9	12
Boost up to Day 7: any grade ≥3 systemic reaction	0	2	2	2

## Statistical analyses

No statistical analyses for this end point

### Primary: The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Prime Immunization up to Boost Immunization or 28 Days After Prime Immunization

End point title	The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Prime Immunization up to Boost Immunization or 28 Days After Prime Immunization <sup>[3]</sup>
-----------------	---

End point description:

Treatment emergent adverse events (TEAEs) were analyzed by age group, dose level, and for each IMP dose. The number and percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade ≥3 TEAE) using the Safety Set. Safety Set - all participants who received at least one dose of the IMP.

End point type	Primary
----------------	---------

End point timeframe:

28 days following first IMP dose or up to second IMP dose (whichever was first)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this primary end point.

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Percentage of participants				
number (not applicable)				
Any TEAE	42	25	25	50
Any grade ≥3 TEAE	0	0	0	0

End point values	Part A	Part A	Part A	Part A
------------------	--------	--------	--------	--------



	Participants Aged 56 to 85 Years - 3 µg	Participants Aged 56 to 85 Years - 10 µg	Participants Aged 56 to 85 Years - 20 µg	Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Percentage of participants				
number (not applicable)				
Any TEAE	17	17	25	42
Any grade ≥3 TEAE	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

### Primary: The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring up to 28 Days After Boost Immunization or After Prime Immunization (if no Boost Immunization)

End point title	The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring up to 28 Days After Boost Immunization or After Prime Immunization (if no Boost Immunization) <sup>[4]</sup>
-----------------	--

End point description:

Treatment emergent adverse events (TEAEs) were analyzed by age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade ≥3 TEAE) using the Safety Set. Safety Set - all participants who received at least one dose of the IMP.

End point type	Primary
----------------	---------

End point timeframe:

28 days following second IMP dose or first IMP dose (if no second IMP dose as given)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this primary end point.

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Percentage of participants				
number (not applicable)				
Any TEAE	50	33	42	50
Any grade ≥3 TEAE	0	0	0	0

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Percentage of participants				

number (not applicable)				
Any TEAE	58	25	42	50
Any grade $\geq 3$ TEAE	0	0	0	8

## Statistical analyses

No statistical analyses for this end point

## Secondary: Functional Antibody Responses

End point title	Functional Antibody Responses
End point description:	
At 7 and 21 days after primary immunization and at 7, 14, 21, 28 days after boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision. 9999 indicates missing Day 36 data of 10 µg and 20 µg younger cohort as they have only re-consented to Clinical Trial Protocol 7.0 (introducing visit 5a/Day 36) on/after their Day 43.	
End point type	Secondary
End point timeframe:	
Up to 50 days following first IMP dose	

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Titer				
geometric mean (confidence interval 95%)				
7 days after Prime Immunization (Day 8)	5.0 (5.0 to 5.0)	5.1 (4.8 to 5.5)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)
21 days after Prime Immunization (Day 22)	6.1 (4.5 to 8.4)	25.9 (13.8 to 48.7)	8.9 (6.0 to 13.3)	12.2 (7.5 to 20.0)
7 days after Boost Immunization (Day 29)	51.5 (26.4 to 100.3)	479.5 (300.3 to 765.5)	106.8 (58.2 to 196.0)	10.0 (6.5 to 15.4)
14 days after Boost Immunization (Day 36)	60.6 (33.5 to 109.8)	9999 (9999 to 9999)	9999 (9999 to 9999)	10.3 (6.9 to 15.4)
21 days after Boost Immunization (Day 43)	36.4 (20.0 to 66.2)	116.5 (79.6 to 170.4)	201.6 (104.9 to 387.2)	9.7 (5.7 to 16.5)
28 days after Boost Immunization (Day 50)	31.7 (18.5 to 54.6)	80.0 (49.1 to 130.4)	219.8 (117.5 to 411.1)	7.9 (5.0 to 12.5)

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12

Units: Titer				
geometric mean (confidence interval 95%)				
7 days after Prime Immunization (Day 8)	5.0 (5.0 to 5.0)	5.0 (5.0 to 5.0)	7.3 (3.2 to 16.6)	5.0 (5.0 to 5.0)
21 days after Prime Immunization (Day 22)	6.3 (4.8 to 8.3)	5.3 (4.9 to 5.8)	15.0 (5.9 to 37.9)	9.4 (5.4 to 16.4)
7 days after Boost Immunization (Day 29)	53.4 (25.1 to 113.7)	51.9 (25.0 to 107.4)	320.0 (189.7 to 539.7)	207.5 (118.0 to 364.8)
14 days after Boost Immunization (Day 36)	77.7 (40.4 to 149.4)	219.8 (148.5 to 325.4)	320.0 (169.3 to 604.9)	359.2 (204.0 to 632.6)
21 days after Boost Immunization (Day 43)	53.4 (27.5 to 103.6)	155.4 (105.0 to 230.1)	285.1 (152.6 to 532.7)	261.4 (136.0 to 502.6)
28 days after Boost Immunization (Day 50)	41.2 (20.5 to 82.8)	138.5 (87.9 to 218.2)	232.9 (131.1 to 413.8)	195.8 (109.4 to 350.6)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Fold Increase in Functional Antibody Titers

End point title	Fold Increase in Functional Antibody Titers
End point description:	
At 7 and 21 days after primary immunization and at 7, 14, 21, and 28 days after the boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision.	
End point type	Secondary
End point timeframe:	
Up to 50 days following first IMP dose	

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Fold rise				
geometric mean (confidence interval 95%)				
7 days after Prime Immunization (Day 8)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.1)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)
21 days after Prime Immunization (Day 22)	1.2 (0.9 to 1.7)	5.2 (2.8 to 9.7)	1.8 (1.2 to 2.7)	2.4 (1.5 to 4.0)
7 days after Boost Immunization (Day 29)	10.3 (5.3 to 20.1)	95.6 (60.1 to 153.1)	21.4 (11.6 to 39.2)	2.0 (1.3 to 3.1)
14 days after Boost Immunization (Day 36)	12.1 (6.7 to 22.0)	9999 (9999 to 9999)	9999 (9999 to 9999)	2.1 (1.4 to 3.1)
21 days after Boost Immunization (Day 43)	7.3 (4.0 to 13.2)	23.3 (15.9 to 34.1)	40.3 (21.0 to 77.4)	1.9 (1.1 to 3.3)
28 days after Boost Immunization (Day 50)	6.3 (3.7 to 10.9)	16.0 (9.8 to 26.1)	44.0 (23.5 to 82.2)	1.6 (1.0 to 2.5)

<b>End point values</b>	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Fold rise				
geometric mean (confidence interval 95%)				
7 days after Prime Immunization (Day 8)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	1.3 (0.8 to 2.1)	1.0 (1.0 to 1.0)
21 days after Prime Immunization (Day 22)	1.3 (1.0 to 1.7)	1.1 (1.0 to 1.2)	2.6 (1.3 to 5.0)	1.9 (1.1 to 3.3)
7 days after Boost Immunization (Day 29)	10.7 (5.0 to 22.7)	10.4 (5.0 to 21.5)	55.4 (35.5 to 86.4)	41.5 (23.6 to 73.0)
14 days after Boost Immunization (Day 36)	15.5 (8.1 to 29.9)	44.0 (29.7 to 65.1)	55.4 (31.2 to 98.4)	71.8 (40.8 to 126.5)
21 days after Boost Immunization (Day 43)	10.7 (5.5 to 20.7)	31.1 (21.0 to 46.0)	49.4 (29.7 to 81.9)	52.3 (27.2 to 100.5)
28 days after Boost Immunization (Day 50)	8.2 (4.1 to 16.6)	27.7 (17.6 to 43.6)	40.3 (26.7 to 60.9)	39.2 (21.9 to 70.1)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline

End point title	Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline
-----------------	--

End point description:

At 7 and 21 days after primary immunization and at 7, 14, 21, and 28 days after the boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision. 9999 indicates missing Day 36 data of 10 µg and 20 µg younger cohort as they have only re-consented to Clinical Trial Protocol 7.0 (introducing visit 5a/Day 36) on/after their Day 43.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 50 days following first IMP dose

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
7 days after Prime Immunization (Day 8)	0	0	0	0
21 days after Prime Immunization (Day 22)	1	9	2	5
7 days after Boost Immunization (Day 29)	9	12	12	3
14 days after Boost Immunization (Day 36)	9	9999	9999	4
21 days after Boost Immunization (Day 43)	8	12	12	3
28 days after Boost Immunization (Day 50)	8	11	12	1

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
7 days after Prime Immunization (Day 8)	0	0	1	0
21 days after Prime Immunization (Day 22)	1	0	4	2
7 days after Boost Immunization (Day 29)	10	10	12	12
14 days after Boost Immunization (Day 36)	11	12	12	12
21 days after Boost Immunization (Day 43)	9	12	12	12
28 days after Boost Immunization (Day 50)	9	12	12	12

## Statistical analyses

No statistical analyses for this end point

## Secondary: Functional Antibody Responses

End point title	Functional Antibody Responses
-----------------	-------------------------------

End point description:

At 63, 162, 365 days after boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision. 9999 indicates Day 387 data is either missing due to exclusion because of non-study vaccination or due to premature discontinuation. 99999 indicates value not evaluable, confidence intervals were only calculated if values of at least 3 participants were available.

End point type	Secondary
End point timeframe:	
From 51 to up to 387 days following first IMP dose	

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Titer				
geometric mean (confidence interval 95%)				
63 days after Boost Immunization (Day 85)	40.0 (22.4 to 71.4)	51.9 (39.1 to 68.9)	116.5 (51.0 to 266.1)	13.0 (7.8 to 21.5)
162 days after Boost Immunization (Day 184)	11.7 (5.8 to 23.8)	51.5 (33.9 to 78.1)	119.9 (62.6 to 229.5)	11.0 (4.7 to 25.8)
365 days after Boost Immunization (Day 387)	197.0 (14.2 to 2727.9)	452.5 (47.4 to 4322.3)	513.3 (215.8 to 1221.2)	5.0 (-99999 to 99999)

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Titer				
geometric mean (confidence interval 95%)				
63 days after Boost Immunization (Day 85)	34.6 (18.1 to 66.1)	85.2 (48.7 to 149.0)	142.5 (77.9 to 260.7)	75.5 (45.6 to 125.0)
162 days after Boost Immunization (Day 184)	9.6 (6.1 to 15.0)	28.3 (11.2 to 71.6)	44.9 (22.0 to 91.8)	107.7 (42.3 to 273.8)
365 days after Boost Immunization (Day 387)	1280.0 (-99999 to 99999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Fold Increase in Functional Antibody Titers

End point title	Fold Increase in Functional Antibody Titers
-----------------	---

End point description:

At 63, 162, 365 days after boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision. 9999 indicates Day 387 data is either missing due to exclusion because of non-study vaccination or due to premature discontinuation. 99999 indicates value not evaluable, confidence intervals were only calculated if values of at least 3 participants were available.

End point type	Secondary
End point timeframe:	
From 51 to up to 387 days following first IMP dose	

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Fold rise				
geometric mean (confidence interval 95%)				
63 days after Boost Immunization (Day 85)	8.0 (4.5 to 14.3)	10.4 (7.8 to 13.8)	23.3 (10.2 to 53.2)	2.6 (1.6 to 4.3)
162 days after Boost Immunization (Day 184)	2.3 (1.2 to 4.8)	10.3 (6.8 to 15.6)	24.0 (12.5 to 45.9)	2.2 (0.9 to 5.2)
365 days after Boost Immunization (Day 387)	39.4 (2.8 to 545.6)	90.5 (9.5 to 864.5)	102.7 (43.2 to 244.2)	1.0 (-99999 to 99999)

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Fold rise				
geometric mean (confidence interval 95%)				
63 days after Boost Immunization (Day 85)	6.9 (3.6 to 13.2)	17.0 (9.7 to 29.8)	24.7 (15.3 to 39.9)	15.1 (9.1 to 25.0)
162 days after Boost Immunization (Day 184)	1.9 (1.2 to 3.0)	5.7 (2.2 to 14.3)	9.0 (4.4 to 18.4)	21.5 (8.5 to 54.8)
365 days after Boost Immunization (Day 387)	256.0 (-99999 to 99999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline

End point title	Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline
-----------------	--

End point description:

At 63, 162, 365 days after boost immunization. Immunogenicity set - all participants who received at least one dose of IMP and had at least one post-baseline functional antibody titer immunogenicity assessment. Boost immunization withheld for 30 µg younger cohort following Safety Review Committee decision. 9999 indicates Day 387 data is either missing due to exclusion because of non-study

vaccination or due to premature discontinuation.

End point type	Secondary
End point timeframe:	
From 51 to up to 387 days following first IMP dose	

End point values	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg	Part A Participants Aged 18 to 55 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
63 days after Boost Immunization (Day 85)	9	12	11	3
162 days after Boost Immunization (Day 184)	4	11	12	2
365 days after Boost Immunization (Day 387)	4	5	11	0

End point values	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: Participants				
63 days after Boost Immunization (Day 85)	8	11	12	12
162 days after Boost Immunization (Day 184)	2	6	6	6
365 days after Boost Immunization (Day 387)	1	9999	9999	9999

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 (Prime Immunization) up to Day 50 (with or without Boost Immunization). Adverse events with an onset date more than 28 days after the last administration of IMP are reported only if assessed as related to IMP by the investigator.

Adverse event reporting additional description:

Treatment emergent adverse events (TEAEs) are reported, i.e., adverse events (AEs) with an onset date on or after the first administration of IMP (if the AE was absent before the first administration of IMP) or worsened after the first administration of IMP (if the AE was present before the first administration of IMP).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

### Reporting groups

Reporting group title	Part A Participants Aged 18 to 55 Years - 3 µg
-----------------------	--

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 18 to 55 Years - 10 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 18 to 55 Years - 20 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 18 to 55 Years - 30 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime regimen only, as decided by the Safety Review Committee).

Reporting group title	Part A Participants Aged 56 to 85 Years - 3 µg
-----------------------	--

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 56 to 85 Years - 10 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 56 to 85 Years - 20 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

Reporting group title	Part A Participants Aged 56 to 85 Years - 30 µg
-----------------------	---

Reporting group description:

BNT162b3: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost [P/B] regimen)

<b>Serious adverse events</b>	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

<b>Serious adverse events</b>	Part A Participants Aged 18 to 55 Years - 30 µg	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

<b>Serious adverse events</b>	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Part A Participants Aged 18 to 55 Years - 3 µg	Part A Participants Aged 18 to 55 Years - 10 µg	Part A Participants Aged 18 to 55 Years - 20 µg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 12 (58.33%)	4 / 12 (33.33%)	5 / 12 (41.67%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Surgical and medical procedures			
Dental care			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tenderness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nasal discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Psychiatric disorders Restlessness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Investigations Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Injury, poisoning and procedural complications Skin laceration subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 12 (16.67%) 2	2 / 12 (16.67%) 2
Hyperaesthesia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Sciatica			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Meibomian gland dysfunction			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Myalgia			

subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Myofascial pain syndrome subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Infections and infestations			
Cystitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Pulpitis dental subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0

<b>Non-serious adverse events</b>	Part A Participants Aged 18 to 55 Years - 30 µg	Part A Participants Aged 56 to 85 Years - 3 µg	Part A Participants Aged 56 to 85 Years - 10 µg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 12 (50.00%)	7 / 12 (58.33%)	5 / 12 (41.67%)
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Surgical and medical procedures Dental care subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
General disorders and administration site conditions Chest pain subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Influenza like illness subjects affected / exposed occurrences (all)  Injection site reaction subjects affected / exposed occurrences (all)  Malaise subjects affected / exposed occurrences (all)  Tenderness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  1 / 12 (8.33%) 1  1 / 12 (8.33%) 1  1 / 12 (8.33%) 1  1 / 12 (8.33%) 1	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  1 / 12 (8.33%) 1  1 / 12 (8.33%) 1  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Nasal discomfort subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Psychiatric disorders Restlessness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Sleep disorder subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Investigations Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Injury, poisoning and procedural complications Skin laceration subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Nervous system disorders			



Dizziness subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1
Headache subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Hyperaesthesia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Eye disorders Meibomian gland dysfunction subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Gastrointestinal disorders Dyspepsia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Flatulence subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Paraesthesia oral subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Skin and subcutaneous tissue disorders			

Pruritus subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	2 / 12 (16.67%) 2	0 / 12 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Myofascial pain syndrome subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Infections and infestations			
Cystitis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Pulpitis dental subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 12 (8.33%) 2	0 / 12 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0
Urinary tract infection			

subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	Part A Participants Aged 56 to 85 Years - 20 µg	Part A Participants Aged 56 to 85 Years - 30 µg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 12 (41.67%)	6 / 12 (50.00%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Surgical and medical procedures			
Dental care			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Influenza like illness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Injection site reaction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	
occurrences (all)	0	1	
Tenderness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Immune system disorders			
Seasonal allergy			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Nasal discomfort subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)  Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	2 / 12 (16.67%) 4  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  1 / 12 (8.33%) 1	
Psychiatric disorders Restlessness subjects affected / exposed occurrences (all)  Sleep disorder subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	
Investigations Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)  Lipase increased subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1  1 / 12 (8.33%) 1	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	
Injury, poisoning and procedural complications			

Skin laceration subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)  Hyperaesthesia subjects affected / exposed occurrences (all)  Sciatica subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1  0 / 12 (0.00%) 0  1 / 12 (8.33%) 1  0 / 12 (0.00%) 0	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  1 / 12 (8.33%) 1	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)  Vertigo subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1  0 / 12 (0.00%) 0	0 / 12 (0.00%) 0  1 / 12 (8.33%) 1	
Eye disorders Meibomian gland dysfunction subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Gastrointestinal disorders Dyspepsia subjects affected / exposed occurrences (all)  Flatulence	1 / 12 (8.33%) 1	0 / 12 (0.00%) 0	

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Paraesthesia oral subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Toothache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Myofascial pain syndrome subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 12 (8.33%) 1	
Infections and infestations Cystitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Oral herpes subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 12 (0.00%) 0	
Pulpitis dental			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Sinusitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	
occurrences (all)	0	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 September 2020	This amendment described changes made to clarify potential inconsistencies, to align trial reporting with other ongoing BNT162 trials, and to enhance assessments for immunogenicity.
02 December 2020	This update implemented: a change in sponsor name; the addition of two additional dosing cohorts in older adults; measures to avoid under reporting of mild COVID-19 related events revealed within the trial; terminology alignment with other ongoing trials; correction to some errors. The rationale for the addition of two older adult cohorts was based on the available immunogenicity and cell-mediated immune response data after dosing with BNT162b1 and BNT162b2 in younger and elderly adults in the BNT162-01 (2020-001038-36) and BNT162-02 (2020-002641-42) trials elicited measurable but lower responses in elderly adults than in younger adults. Therefore, the additional older adult cohorts were to be used to investigate BNT162b3 doses above the already tested 20 µg BNT162b3 dose, to support any future Phase III program planned to support marketing approval.
25 March 2021	This update implemented the removal of Part B, changes to the primary objective endpoints, and a change to concomitant medication reporting during study follow-up to allow capture of vaccinations, e.g., SARS-CoV-2 vaccinations.
12 May 2021	This update implemented corrections to time points in the exploratory objectives and a deletion within Section 4.4 (End of Treatment and end of trial definition) in order to allow subjects to participate in other clinical trials investigating COVID-19 vaccines and treatments.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported